Christine Messmer PC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 3,662 shares of the medical research company’s stock, valued at approximately $1,199,000. Amgen makes up 0.8% of Christine Messmer PC’s holdings, making the stock its 27th biggest holding.
Other institutional investors also recently made changes to their positions in the company. Board of the Pension Protection Fund purchased a new stake in Amgen during the 4th quarter worth $26,000. Olistico Wealth LLC purchased a new stake in Amgen during the 4th quarter worth $33,000. Cloud Capital Management LLC purchased a new stake in Amgen during the 3rd quarter worth $34,000. Ares Financial Consulting LLC purchased a new stake in Amgen during the 4th quarter worth $34,000. Finally, Saranac Partners Ltd purchased a new stake in Amgen during the 3rd quarter worth $37,000. 76.50% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts recently weighed in on the stock. Royal Bank Of Canada upped their price target on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Daiwa Securities Group upped their price target on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Leerink Partners reaffirmed a “market perform” rating and set a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Canaccord Genuity Group assumed coverage on shares of Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price target for the company. Finally, Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $357.12.
Amgen News Summary
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Amgen announced an additional $300 million investment to expand and modernize its U.S. manufacturing footprint in Juncos, Puerto Rico — part of nearly $2 billion of U.S. manufacturing investment over the last year; this strengthens capacity, supply resilience and long-term revenue support. AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
- Neutral Sentiment: Coverage of the Puerto Rico expansion by major outlets (Reuters, Quartz) highlights the same investment news — useful for validation but not new catalyst beyond the company release. Amgen to invest additional $300 million to boost US manufacturing footprint
- Neutral Sentiment: Health-care stocks were softer in afternoon trade, which can amplify selling in large-cap biopharma names like Amgen even when company fundamentals are unchanged. Sector Update: Health Care Stocks Softer in Afternoon Trading
- Neutral Sentiment: A Zacks note flagged increased investor attention to AMGN; this signals higher scrutiny/flow but doesn’t itself imply directional catalyst. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
- Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 from $351 and kept a Neutral rating — a modest cut but enough to pressure sentiment because it lowers upside expectations versus recent levels. Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
Amgen Stock Performance
NASDAQ:AMGN opened at $323.85 on Tuesday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 0.90. The firm has a 50-day moving average of $358.07 and a two-hundred day moving average of $341.12. The stock has a market cap of $174.78 billion, a P/E ratio of 22.54, a PEG ratio of 3.24 and a beta of 0.44. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29.
Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts expect that Amgen Inc. will post 22.28 earnings per share for the current fiscal year.
Amgen Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.15%.
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Articles
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
-2028-municipal-bond-etf-logo-1200x675.jpg){kind=logo}
